Navigation Links
Andrew Powell Joins InterMune As Executive Vice President And General Counsel
Date:9/24/2013

BRISBANE, Calif., Sept. 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Andrew Powell has joined InterMune as Executive Vice President, General Counsel and Corporate Secretary.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Mr. Powell will be responsible for managing the company's legal affairs.  He will report to Dan Welch, Chairman, Chief Executive Officer and President of InterMune.

Mr. Welch said, "Andrew brings experience in many areas that are key to InterMune's future as our Esbriet sales continue to grow globally, and we plan for anticipated approval and launch of Esbriet in the United States."

Mr. Powell's experience spans two decades of leadership in the life sciences, most recently as Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics. Mr. Powell has practiced law for more than 25 years, principally in healthcare and biotechnology.  He held positions of increasing responsibility for more than 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology.  Mr. Powell then served as SVP and General Counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly.

Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com/.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
2. Eppendorf Video Features Dr Andrew Holts Work on Bioactive Leachates From Plastic Consumables
3. Green Dot Holdings LLC CEO, Mark Remmert, Joins Industry Thought Leaders to Discuss Holistic Sustainable Design at A Better World by Design Conference
4. Robert Tungatt, Regulatory Compliance and Cold Chain Excellence Specialist Joins QuickSTAT
5. Chinese Leader in Genomics Joins Science Center's Port Community
6. Greg Plum Joins the SoundConnect Team
7. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
8. Dik Barsamian Joins the US HealthConnect Inc. Group of Companies as the New President of Its CME Enterprises
9. Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
10. Jeffrey Toobin Joins Gateway Public Schools for the 2013 Matters of the Mind Luncheon
11. Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- BERG, a biopharmaceutical company uncovering health solutions ... the appointment of Jason Haddock as ... brings to BERG over 20 years of experience ... financial functions at pharmaceutical companies, as well as ... Niven R. Narain , BERG,s Chief ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016 Should ... standard bone cement products to prevent infection after standard ... that the experts at ECRI Institute have been fielding ... Infection or Fighting Your Bottom Line?" ... Your Bottom Line?" --> While ...
(Date:2/8/2016)... 8, 2016 Novan, Inc. today announced that Director ... of Directors of Novan. In addition, Robert Keegan has ... North Carolina . --> North Carolina ... it received a total of $32.8 million of net proceeds in ... investor network originating throughout the Research Triangle area of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Information Management Services ( ... The upgrade represents a completely new technical foundation and is so significant it ... responsive design interface, significantly increased speed for search results, a streamlined layout and a ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... Feb. 2, 2016 This BCC Research ... market by reviewing the recent advances in high ... drive the field forward. Includes forecast through 2019. ... the challenges and opportunities that exist in the ... solution developers, as well as IT and bioinformatics ...
Breaking Biology News(10 mins):